Susmed (TSE:4263) Current Deferred Revenue: 円0.0 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4263 Susmed Inc TSE:4263
64 GF Score
Price 円549.00
GF Value 円941.10
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Susmed Current Deferred Revenue?

Susmed TSE:4263 +3.58% 64 Current Deferred Revenue is 円0.0 Mil as of Dec. 2025. GuruFocus rates TSE:4263 with a GF Score™ of 64/100 and a GF Value™ of 円941.10 (Possible Value Trap). The stock has 1 warning sign investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Susmed's current deferred revenue for the quarter that ended in Dec. 2025 was 円0.0 Mil.

Susmed Current Deferred Revenue Related Terms

Susmed Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Susmed's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Susmed Current Deferred Revenue Chart

Susmed Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Current Deferred Revenue
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Susmed Quarterly Data
Jun20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSE:4263
64GF Score
Susmed Inc TSE:4263
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of 円0.0 Mil mean?
Susmed (TSE:4263) has a Current Deferred Revenue of 円0.0 Mil as of Dec. 2025. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Susmed and its competitors.
Is Susmed's Current Deferred Revenue too high?
Susmed's current Current Deferred Revenue is 円0.0 Mil. Overall, Susmed has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Susmed's Current Deferred Revenue compare to VEEV and BTSG?
Susmed's Current Deferred Revenue of 円0.0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Healthcare Providers & Services company?
A good Current Deferred Revenue depends on the Healthcare Providers & Services industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Susmed and its competitors. Susmed's current Current Deferred Revenue is 円0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Susmed stock overvalued right now?
Based on GuruFocus' analysis, Susmed (TSE:4263) is currently considered Possible Value Trap. The stock's GF Value™ is 円941.10, compared to a current price of 円549.00 — trading 41.7% below its estimated fair value. The current Current Deferred Revenue is 円0.0 Mil. Susmed's overall GF Score™ is 64/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Susmed (TSE:4263), the current Current Deferred Revenue is 円0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Susmed (TSE:4263) Overvalued in 2026?

Based on GuruFocus' analysis, Susmed stock appears to be undervalued. The current stock price of 円549.00 is trading 41.7% below its estimated GF Value™ of 円941.10. GuruFocus considers Susmed to be Possible Value Trap.

Key valuation signals for TSE:4263:

  • Current Deferred Revenue: 円0.0 Mil
  • GF Value™: 円941.10 vs. price of 円549.00 (41.7% below fair value)
  • GF Score™: 64/100 with 1 warning sign

No single metric tells the full story. See the TSE:4263 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Susmed Business Description

Address 3-7-2 Nihonbashi Honcho, 10th Floor, MFPR Nihonbashi Honcho Building, Chuo-ku, Tokyo, JPN, 103-0023
Susmed Inc is engaged in the development of therapeutic smartphone apps and digital solutions to streamline clinical trials. It is currently developing therapeutic apps for patients with insomnia, breast cancer, kidney disease, and other conditions. In addition, it has developed Susumed System, which uses a proprietary blockchain technology to ensure the reliability of clinical trial data, and can reduce the manpower and costs allocated to clinical trials. The company's reportable segments are: the DTx Product Business, which derives maximum revenue, and consists of the development of therapeutic apps; and the DTx Platform Business, which provides general-purpose clinical trial systems and machine learning automated analysis systems.
64GF Score

Get the complete analysis for TSE:4263

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円549.00
Price
円941.10
GF Value